Worldwide prevalence (major markets) of #RA was 4.9 million in 2020; the RA global treatment market is estimated at US $40.5 billion in 2021, and is expected to grow ~6% per year in the next decade. https://t.co/EtBQwru0uF https://t.co/BRLtnwxc2b

Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/9NjlIExl8c https://t.co/vaRJjwOu2q

Enthesitis portends worse SpA. Data from 749 SpA pts in REGISPONSER-AS registry found 6.1% w/achilles tendinitis at baseline. Pts w/ enthesitis had worse pain, BASDAI, mBASDAI, ASDAS-CRP scores & after 2 yrs had fewer in low dz state (16 vs 31.5%) https://t.co/sChQ4WFmlW https://t.co/BkjzxCQIGF

RA Disease Activity and Alcohol Use The effects of alcohol use in RA is less known, but a study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients. https://t.co/u6ZjZ7o1Hq https://t.co/S9JPXMJVZo

AR882, selective uric acid transporter 1 (URAT1) inhibitor in development, completed a phase 2, 140 pt 12-week PBO controlled trial, where 75 mg/d lowered SUA by 59% (8.6 to 3.5 ) & 42% (8.6 to 5.0 ) in 50 mg dose group - all better than PBO https://t.co/HHzHWj4XQr https://t.co/gJD9hnkFJc

Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended. But don't take our word for it, last year's attendees say: "Great conference. Best in the last year. I did Hopkins, CCR, and ACR too" https://t.co/Im6xStFwOw https://t.co/NhdbkNo1jl

Ferritin may be more than biomarker in Stills, etc - may contribute directly to pathogenesis. Ferritin causes PMN activation & neutrophil extracellular traps (NETs). Could this be targeted therapeutically? https://t.co/tHbS6WtNWp https://t.co/rXfqgkij7k

Worse Birth Outcomes in RA and SLE A population-based retrospective cohort study patients with RA or SLE and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE. https://t.co/oK05W8ncW0 https://t.co/3eJzHHOvXO

Half of all outpt. MDs are bound by restrictive covenants. FTC is considering a ban on noncompete clauses. AMA) code of ethics discourages covenants that "unreasonably restrict". FTC the rule change could save Pts up to $148 billion https://t.co/nssfbrxnLR https://t.co/8hGArfGEGW

173 PsA pts enrolled to start ustekinumab: half on MTX and half on PBO. At week 24 there was no difference in DAS28 between groups (2.9 vs 3.1); then Ustekinumab plus placebo was non-inferior to ustekinumab plus methotrexate https://t.co/AygtawIZsZ https://t.co/YLGp5lMWT9

ACP Guidelines on Fracture Prevention in at-risk Adults The American College of Physicians (ACP) has updated its 2017 recommendations on pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults. https://t.co/e7qaNCXUnx https://t.co/yys4MXMyOd